Silexion Therapeutics to Present New Cancer Treatment Data at Major Symposium
Chicago, Monday, 13 January 2025.
Silexion Therapeutics will present promising data on their cancer treatment, SIL-204, at the 2025 ASCO Gastrointestinal Cancers Symposium, potentially impacting future cancer therapies and their industry standing.
Company Overview and Upcoming Presentation
Silexion Therapeutics Corp (NASDAQ: SLXN), a clinical-stage biotechnology company, will present new data for their KRAS-driven pancreatic cancer treatment at the prestigious ASCO Gastrointestinal Cancers Symposium [1]. The presentation, scheduled for January 24, 2025, will focus on their innovative SIL-204 siRNA therapy, which targets specific KRAS mutations including G12x, Q61H, and G13D [1]. The symposium, taking place in San Francisco from January 23-25, 2025, is a specialized meeting showcasing the latest developments in gastrointestinal cancer treatment [1].
Market Position and Financial Challenges
Despite the promising clinical developments, Silexion faces significant market challenges. The company’s stock has recently touched a 52-week low of $1.82, with a market capitalization of just $2.99 million [2]. The company has experienced a dramatic decline in stock value, with a -98.04 percent change over the past year [2]. In response to these challenges, Silexion has implemented a 1-for-9 reverse share split and adjusted its warrant exercise price to $103.50 per share [2].
Clinical Development Pipeline
Silexion is advancing its therapeutic pipeline with two key products. Their first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer [1]. The company is also preparing to move SIL-204 into Phase 2/3 clinical trials, scheduled to begin in the first half of 2026 [2]. This development timeline positions Silexion to potentially deliver new treatment options for patients with KRAS-driven cancers [1].
Corporate Leadership Changes
In recent corporate developments, Silexion announced the immediate resignation of board member Ilan Shiloah, creating vacancies in key committees including audit, compensation, and corporate governance [2]. This leadership change comes at a crucial time as the company navigates both clinical advancement and market challenges [2].